Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 48Arthralgia 3Advanced Breast Cancer 3Polycystic Ovary Syndrome 2Osteoporosis 2Fractures, Bone 2Carcinoma, Intraductal, Noninfiltrating 2Breast Diseases 2Breast Cancer Female 2Sexuality 1Sexual Dysfunctions, Psychological 1Neurotoxicity Syndromes 1Neoplasm Metastasis 1Luminal B/HER2-negative Breast Cancer 1Leiomyoma 1Infertility 1Hormone-receptor-positive Breast Cancer 1Hormone Receptor Positive Breast Carcinoma 1Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer 1HR+/HER2- Early Breast Cancer 1HR+/HER2+ Early Breast Cancer 1Fatigue 1Estrogen Receptor and/or Progesterone Receptor Positive 1Endometrial Stromal Tumors 1Endometrial Neoplasms 1Bulbo-Spinal Atrophy, X-Linked 1Breast Carcinoma In Situ 1Breast Cancer Metastatic 1Bone Diseases, Metabolic 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Aromatase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Luminal B/HER2-negative Breast Cancer × Aromatase Inhibitors × Clear all
NCT05640778 2024-01-31

Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Unknown
30 enrolled
Breast

Luminal B/HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡